


1FW



PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on


Jane A. Walker

September 16, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rothenberg et al.
Application No.: 10/752,659
Filed: January 7, 2004
Title: **CYTOKINE INHIBITION OF EOSINOPHILS**
Art Unit: 1614
Examiner: Unknown
Conf. No.: 4105
Atty. Docket No.: CMC-161

Cincinnati, Ohio

September 16, 2004

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §§1.97 and 1.98, Applicants call the references listed on the attached PTO-1449 form to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Applicants have enclosed a copy of the cited references.

Certification Under 37 C.F.R. § 1.704(d)

Each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application and was not received by any person designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

These references were cited in an International Search Report dated August 10, 2004 and received on August 16, 2004 for a related foreign application.

No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and make an independent evaluation of their materiality.


A first Office Action has not yet been issued. Therefore, Applicants do not believe that any fees are due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,
WOOD, HERRON & EVANS, L.L.P.

By: Beverly A. Lyman
Beverly A. Lyman, Ph.D.
Reg. No. 41,961

Wood, Herron & Evans, L.L.P.
2700 Carew Tower
Cincinnati, OH 45202
513 241-2324
513 421-7269 facsimile

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.									
(37 CFR 1.98(b)) Use several sheets if necessary)													
				FILING DATE January 7, 2004		GROUP Unknown							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	5	8	7	1	7	2	3	02/16/99	Strieter et al.	424	85.1	06/06/1995
	A.B												
	A.C												
	A.D												
	A.E												
	A.F												
	A.G												
	A.H												
	A.I												
	A.J												
	A.K												
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER			PUBLICATION DATE			COUNTRY OR PATENT OFFICE			CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	WO0162274			08/03/2001			PCT - Spain			A61K	38/19	Abstract only
	A.M	WO9421277			09/29/2004			PCT - US			A61K	37/O2	N/A
	A.N	WO9404670			03/03/1994			PCT - US			C12N	15/O0	N/A
	A.O												
	A.P												
	A.Q												
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	A.R	PCT, <u>International Search Report</u> , PCT/US2004/O00199, dated August 10, 2004, 6 pages											
	A.S	Kaplan AP, <u>Chemokines, Chemokine Receptors and Allergy</u> , International Archives of Allergy and Immunology 124(4):423-431 (2001), XP009034299											
	A.T	Medoff B et al., <u>IFN-γ-Inducible Protein 10 (CXCL10) Contributes to Airway Hyperreactivity and Airway Inflammation in a Mouse Model of Asthma</u> , The Journal of Immunology 168(10):5278-5287 (2002), XP002289900											
EXAMINER										DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p> <p>(37 CFR 1.98(b))</p>				APPLICANT Mark Elliot Rothenberg et al.			
				FILING DATE January 7, 2004	GROUP Unknown		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Sgadari C et al., <u>Mig, the Monokine Induced by Interferon-γ, Promotes Tumor Necrosis in Vivo</u> , Blood 89 (8):2635-2643 (1997)					
	B.S	Thomas MS et al., <u>Role of IP-10 in a Cockroach Antigen Induced Muring Model of Airway Hyperreactivity</u> , FASEB Journal 16(4):A331 (2002) XP009034300, Abstract 245.3					
	B.T						
EXAMINER				DATE CONSIDERED			
<p>EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.</p>							